ArticleDiabetes2009
Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes.
Article in Diabetes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.Endocrine · 2020Pooled it
- Renin-angiotensin system blockade for the risk of cancer and death.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2016Pooled it
- Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes.Diabetologia · 2026Article
- Association of visceral adipose tissue with albuminuria and interaction between visceral adiposity and diabetes on albuminuria.Acta diabetologica · 2024Article
- Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes.British journal of cancer · 2023Article
- LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug.Life science alliance · 2023Article
- Risk for cancer in living kidney donors and recipients.Journal of cancer research and clinical oncology · 2018Review
- Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program.Endocrinology and metabolism (Seoul, Korea) · 2018Review
- Article
- Drug-subphenotype interactions for cancer in type 2 diabetes mellitus.Nature reviews. Endocrinology · 2015Review
- Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.BMC medicine · 2014Article
- Statins and the risk of gastric cancer in diabetes patients.BMC cancer · 2012Article
- Cancer risk in type 2 diabetes.Current diabetes reports · 2012Article
- Diabetes, insulin and cancer risk.World journal of diabetes · 2012Article
- Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression.Diabetes · 2012Article
- The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry.Current cardiovascular risk reports · 2011Article
- Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer.Diabetologia · 2011Article
- Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.Diabetes care · 2011Article
- Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.Diabetes · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClinical and experimental studies suggest cross-talk between lipid metabolism and the renin-angiotensin system (RAS) in atherogenesis. The aim of this study was to explore interactions between these two systems in mediating cancer risk in type 2 diabetes. RESEARCH DESIGN AND
methodsA prospective cohort of 4,160 Chinese patients with type 2 diabetes, free of cancer at enrollment, were analyzed using Cox models. Interaction of RAS inhibitors (angiotensin I-converting enzyme inhibitors or angiotensin II receptor blockers) and statins was estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S). RERI > 0, AP > 0, or S > 1 indicates additive interaction between the two classes of drugs. Molecular mechanisms underlying these interactions were explored using a uninephrectomy (UNX) rat model with renal carcinogenesis.
resultsDuring 21,992 person-years of follow-up, 190 patients developed cancer. Use of RAS inhibitors and statins in isolation or combination during follow-up was associated with reduced risk of cancer after adjustment for covariates. The multivariable RERI and AP for the additive interaction between these drug classes for cancer were significant (0.53 [95% CI 0.20-0.87] and 2.65 [0.38-4.91], respectively). In the UNX rat model, inhibition of the RAS prevented renal cell carcinoma by normalizing hydroxymethylglutaryl-CoA reductase (HMGCR) expression and the insulin-like growth factor-1 (IGF-1) signaling pathway.
conclusionsCombined use of RAS inhibitors and statins may act synergistically to reduce cancer risk, possibly via HMGCR and IGF-1 signaling pathways in high-risk conditions such as type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.